TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9838127

Group type: EXPERIMENTAL
Intervention: FGF-9 immunoreactivity in Alzheimer's disease (AD) brains
Number of subjects: 0

Group type: COMPARATOR
Intervention: FGF-9 immunoreactivity in control cases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGF-9 immunoreactive astrocytes in AD brains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amyloid core and neurofibrillary tangles
Number of subjects: 0
Study: 8033503

Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-vasopressin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Indocyanine Green clearance
Number of subjects: 9
Study: 2610781

Group type: EXPERIMENTAL
Intervention: Routine care plus one‐to‐one support by an experienced monitrice
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine nursing care (controls)
Number of subjects: 103
Study: 29504416

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT), n=28, 12 weeks, 3 times a week, 2 sets of 15-20 repetitions
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (CON), n=24, sham-exercise with active mobilization
Number of subjects: 52
Study: 28703936

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 59
Study: 26132356

Group type: EXPERIMENTAL
Intervention: Wheelie training on a ramp (ramp group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional training (conventional group)
Number of subjects: 52
Study: 22946966

Group type: EXPERIMENTAL
Intervention: Single-dose (SD) antibiotic prophylaxis with second-generation cephalosporin and metronidazole
Number of subjects: 93

Group type: COMPARATOR
Intervention: Three-dose (MD) antibiotic prophylaxis with second-generation cephalosporin and metronidazole
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Single-dose (SD) antibiotic prophylaxis
Number of subjects: 93

Group type: COMPARATOR
Intervention: Three-dose (MD) antibiotic prophylaxis
Number of subjects: 93
Study: 21082476

Group type: EXPERIMENTAL
Intervention: Enhanced infant mental health oriented case management services
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (no enhanced case management)
Number of subjects: 144
Study: 18583047

Group type: EXPERIMENTAL
Intervention: Oral opioids (OP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-opioid analgesics (NOP)
Number of subjects: 110
Study: 16646121

Group type: EXPERIMENTAL
Intervention: Computerized neuropsychological rehabilitation (NR), 10-session adjunctive program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard substance abuse treatment (no adjunctive NR)
Number of subjects: 19
Study: 14564328

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin combination (C+A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Aspirin alone (A)
Number of subjects: 50
Study: 11128566

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) and leucovorin (LCV) - dose intense regimen (biweekly)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU) and leucovorin (LCV) - standard regimen (monthly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) and leucovorin (LCV) - both regimens
Number of subjects: 47
Study: 8844445

Group type: EXPERIMENTAL
Intervention: Procanbid (1,000, 2,000, or 4,000 mg/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Procan SR (1,000, 2,000, or 4,000 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 1470454

Group type: EXPERIMENTAL
Intervention: Sulfacetamide/prednisolone otic drops for 3 days postoperatively
Number of subjects: 430

Group type: COMPARATOR
Intervention: No drops (control group)
Number of subjects: 430
Study: 6387360

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29111902

Group type: EXPERIMENTAL
Intervention: Cranberry juice (240 mL daily)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo (240 mL daily)
Number of subjects: 373
Study: 28383600

Group type: EXPERIMENTAL
Intervention: Intraosseous injection with 4% articaine and 1:100,000 epinephrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block
Number of subjects: 70
Study: 24695100

Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC) treatments, 30 treatments at -130°C for 3 minutes each
Number of subjects: 45
Study: 22544292

Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WBMRI)
Number of subjects: 33
Study: 19719817

Group type: EXPERIMENTAL
Intervention: Modafinil/fentanyl/midazolam
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo/fentanyl/midazolam
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Modafinil/remifentanil/propofol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo/remifentanil/propofol
Number of subjects: 67
Study: 18564958

Group type: EXPERIMENTAL
Intervention: Group music intervention (60 minutes for 15 sessions, 1 or 2 times weekly)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 26
Study: 16094908

Group type: EXPERIMENTAL
Intervention: Four-layer compression bandaging (4LB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual system of care (control)
Number of subjects: 200
Study: 11915491

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations
Number of subjects: 143

Group type: COMPARATOR
Intervention: Albuterol (0.15 mg/kg) - six nebulizations (control group)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (250 micrograms) with albuterol (0.15 mg/kg) - three nebulizations followed by three additional albuterol nebulizations
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide with albuterol in children less than six years of age
Number of subjects: 143
Study: 9440092

Group type: EXPERIMENTAL
Intervention: D-thyroxine 6 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 7879725

Group type: EXPERIMENTAL
Intervention: 15-minute trance duration
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Morning alertness
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Evening alertness
Number of subjects: 95

Group type: COMPARATOR
Intervention: Temperature and light
Number of subjects: 95
Study: 2118299

Group type: EXPERIMENTAL
Intervention: Invasive treatment (angiography and angioplasty)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 201
Study: 368823

Group type: EXPERIMENTAL
Intervention: Double blind method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wide experimentation with critical clinician assessment
Number of subjects: 0
Study: 31126582

Group type: EXPERIMENTAL
Intervention: Music Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 28288636

Group type: EXPERIMENTAL
Intervention: 4-week Smartphone-Based Coronary Heart Disease Prevention (SBCHDP) programme
Number of subjects: 80

Group type: COMPARATOR
Intervention: Health promotion websites
Number of subjects: 80
Study: 26675051

Group type: EXPERIMENTAL
Intervention: FINDRISC questionnaire
Number of subjects: 772
Study: 24784466

Group type: EXPERIMENTAL
Intervention: Trocar placement technique for eLRP and eRALP in patients with lower abdominal incision scars (Group 1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Trocar placement technique for eLRP and eRALP in patients without previous surgeries (Group 2)
Number of subjects: 57
Study: 22526730

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate 72 mg daily for 5 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate flexible dosage up to 1.3 mg/kg body weight during 47-week open-label extension
Number of subjects: 30
Study: 19602907

Group type: COMPARATOR
Intervention: Peritoneal dialysis patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 205
Study: 17690120

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug daily
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study: 15070878

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gonadotrophin therapy
Number of subjects: 0
Study: 12048274

Group type: EXPERIMENTAL
Intervention: Trastuzumab as adjuvant therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Local laboratory testing
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Central HercepTest and central FISH assays
Number of subjects: 119
Study: 9032531

Group type: EXPERIMENTAL
Intervention: 1 day antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7 days antibiotic prophylaxis (cefuroxime or ciprofloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8497383

Group type: EXPERIMENTAL
Intervention: 250 mg methylprednisolone succinate (Solu-Medrol)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 500 mg methylprednisolone succinate (Solu-Medrol)
Number of subjects: 56
Study: 3549319

Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy) administered for not more than 6 months at a maximum dosage of 10 mg/kg for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30658560

Group type: EXPERIMENTAL
Intervention: Weight-loss resilient women
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonresilient women
Number of subjects: 50
Study: 29573263

Group type: EXPERIMENTAL
Intervention: Pre-operative intravenous (IV) methylprednisolone (MP) 125 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isotonic saline (C)
Number of subjects: 59
Study: 24472058

Group type: EXPERIMENTAL
Intervention: levocetirizine plus hydroxyzine
Number of subjects: 24

Group type: COMPARATOR
Intervention: levocetirizine monotherapy
Number of subjects: 24
Study: 22249941

Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5-25 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional Japanese diet
Number of subjects: 51
Study: 17933744

Group type: EXPERIMENTAL
Intervention: Mortality salience manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 0
Study: 16099227

Group type: EXPERIMENTAL
Intervention: Intermittent compression therapy for 2 hours a day for 6 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Calcium (1 g daily) and Vitamin D (800 IU daily)
Number of subjects: 37
Study: 14499318

Group type: EXPERIMENTAL
Intervention: haloperidol 15 mg/day plus ethinyl estradiol 0.05 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: haloperidol 15 mg/day plus placebo
Number of subjects: 32
Study: 11005607

Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated 1% clindamycin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1% clindamycin solution (Klimicin T, Lek)
Number of subjects: 0
Study: 8610864

Group type: EXPERIMENTAL
Intervention: Dural puncture with a 26-gauge Whitacre spinal needle (no drug injected)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no dural puncture)
Number of subjects: 40
Study: 1357297

Group type: EXPERIMENTAL
Intervention: 4 weeks anticoagulation
Number of subjects: 712

Group type: COMPARATOR
Intervention: 3 months anticoagulation
Number of subjects: 712
Study: 3917304

Group type: EXPERIMENTAL
Intervention: Cefamandole 2 grams intramuscularly 30 minutes before operation and 2 grams every eight hours for two days postoperatively
Number of subjects: 52

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 52
Study: 3324612

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycodone plus fentanyl
Number of subjects: 60
Study: 31722544

Group type: EXPERIMENTAL
Intervention: Positive change in FV intake
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Positive change in self-reported PA
Number of subjects: 168
Study: 30371686

Group type: EXPERIMENTAL
Intervention: 2.0 kg palpation stimulus
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 kg palpation stimulus for 5 seconds
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5 kg palpation stimulus
Number of subjects: 30
Study: 25300984

Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist) at a dose of 0.1 mmol/kg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Gadoteridol (ProHance) at a dose of 0.1 mmol/kg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Gadobutrol
Number of subjects: 229

Group type: COMPARATOR
Intervention: Gadoteridol
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Gadobutrol and Gadoteridol
Number of subjects: 229
Study: 23437796

Group type: EXPERIMENTAL
Intervention: Direct current cardioversion (DCC) successful patients (n = 39)
Number of subjects: 153

Group type: COMPARATOR
Intervention: AF recurrence patients (n = 15)
Number of subjects: 153

Group type: COMPARATOR
Intervention: AF patients (n = 153)
Number of subjects: 153
Study: 21701167

Group type: EXPERIMENTAL
Intervention: Omacor™ 1 g/day (DHA/EPA ratio 1.25:1.0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Omacor™ 2 g/day
Number of subjects: 30
Study: 17905178

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Human Insulin (HI)
Number of subjects: 322
Study: 16449511

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10702452

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 0.75 microg/mL
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 1.0 microg/mL
Number of subjects: 120

Group type: COMPARATOR
Intervention: ropivacaine 0.2% wt/vol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% wt/vol + sufentanil 0.5 microg/mL
Number of subjects: 120
Study: 9101388

Group type: EXPERIMENTAL
Intervention: Medically supervised exercise training program for 6 months
Number of subjects: 171
Study: 7645792

Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT, n = 12)
Number of subjects: 29

Group type: COMPARATOR
Intervention: General Anesthesia (GA, n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PRemedication with benzodiazepine (PR, n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Total group (all treatments)
Number of subjects: 29
Study: 2936766

Group type: EXPERIMENTAL
Intervention: Midazolam taken one hour before a meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Midazolam taken with a meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Midazolam taken one hour after a meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (fasting conditions)
Number of subjects: 18
Study: 30183739

Group type: EXPERIMENTAL
Intervention: Flipped classroom
Number of subjects: 108

Group type: COMPARATOR
Intervention: Traditional lecture‐based classroom (control)
Number of subjects: 108
Study: 26564381

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 1839

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1839
Study: 25156397

Group type: EXPERIMENTAL
Intervention: Counselors' use of openness techniques
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Counselors' use of awareness techniques
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Counselors' use of activation techniques
Number of subjects: 44
Study: 23253298

Group type: EXPERIMENTAL
Intervention: Collagen sealant patch (CSP) plus standard treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 70
Study: 20458443

Group type: EXPERIMENTAL
Intervention: hMSH2 gIVS12-6T/C polymorphism
Number of subjects: 96

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy (cisplatin or carboplatin)
Number of subjects: 96
Study: 18766034

Group type: EXPERIMENTAL
Intervention: Interactive digital education aid
Number of subjects: 133

Group type: COMPARATOR
Intervention: Routine assessment and education
Number of subjects: 133
Study: 15943543

Group type: EXPERIMENTAL
Intervention: Contingent group receiving monetary vouchers for CO levels of 8 ppm or less
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontingent group receiving vouchers regardless of CO level
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study: 25327732

Group type: EXPERIMENTAL
Intervention: YAZ (drospirenone 3 mg and ethinylestradiol 20 microg)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: YAZ
Number of subjects: 187
Study: 10362048

Group type: EXPERIMENTAL
Intervention: N-isobutyrylcysteine (NIC) 300 mg b.i.d. for 24 weeks
Number of subjects: 637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: N-isobutyrylcysteine (NIC)
Number of subjects: 637
Study: 7595717

Group type: EXPERIMENTAL
Intervention: lenograstim 5 micrograms/kg/d by once‐daily injection from day 4 to day 13
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo (vehicle)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: lenograstim
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 2406695

Group type: EXPERIMENTAL
Intervention: Infant stimulation followed by physical therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Neurodevelopmental physical therapy
Number of subjects: 48
Study: 7425833

Group type: EXPERIMENTAL
Intervention: 100 mg of phenytoin orally the evening before and on the morning of the operation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 200 mg of phenytoin orally the evening before and on the morning of the operation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 90
Study: 31383723

Group type: COMPARATOR
Intervention: Standard letter (general information)
Number of subjects: 7540

Group type: COMPARATOR
Intervention: Descriptive norms letter (peer comparisons)
Number of subjects: 7540

Group type: COMPARATOR
Intervention: Injunctive norms letter (appeal to authority)
Number of subjects: 7540

Group type: COMPARATOR
Intervention: Combination norms letter (both social norms)
Number of subjects: 7540
Study: 30286737

Group type: EXPERIMENTAL
Intervention: Direct delivery of an HIV self-test
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Delivery of a coupon for an HIV self-test at nearby health clinics
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Standard HIV testing services
Number of subjects: 1382
Study: 27099248

Group type: EXPERIMENTAL
Intervention: High amino acid intake (Imm‐RDI)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Low amino acid intake (Inc‐AAs)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Multicomponent lipid emulsion (SMOF)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Soybean oil (SO) lipid emulsion
Number of subjects: 168
Study: 25262617

Group type: EXPERIMENTAL
Intervention: Advocate(®) (2.5% moxidectin+10% imidacloprid) applied monthly, biweekly, or weekly
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral ivermectin (IVR) at 500 μg/kg daily
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Advocate(®) (2.5% moxidectin+10% imidacloprid)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 58
Study: 22709744

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (150 mg to 300 mg twice a day, adjusted based on creatinine clearance and plasma levels)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Warfarin (dosing according to current practice guidelines)
Number of subjects: 405
Study: 20067626

Group type: COMPARATOR
Intervention: Standard printed PA educational materials provided by the Canadian Diabetes Association (Group 1/control group)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Standard printed PA educational materials, pedometers, a log book, and printed PA information matched to individuals' PA stage of readiness provided every 3 months (Group 2)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: PA telephone counseling protocol matched to PA stage of readiness and tailored to personal characteristics, in addition to the materials provided in Groups 1 and 2 (Group 3)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Group 2 and Group 3 relative to Group 1
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Clinical (biomarkers) and health‐related quality of life assessments
Number of subjects: 287
Study: 17336514

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 946

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 946
Study: 15932790

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (800 IU/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 34
Study: 12205728

Group type: EXPERIMENTAL
Intervention: Sevoflurane-nitrous oxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Target-controlled propofol with fentanyl
Number of subjects: 40
Study: 9839841

Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 10

Group type: COMPARATOR
Intervention: Overground running
Number of subjects: 10
Study: 7994785

Group type: EXPERIMENTAL
Intervention: 20 mg Adriamycin (group A)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 20 mg epirubicin (group B)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 20 mg pirarubicin (group C)
Number of subjects: 299

Group type: COMPARATOR
Intervention: PS alone (group D, control)
Number of subjects: 299
Study: 2726146

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (300 USP units)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 30021178

Group type: EXPERIMENTAL
Intervention: Family Unification Program (FUP) plus housing advocacy
Number of subjects: 89

Group type: COMPARATOR
Intervention: Housing advocacy alone
Number of subjects: 89
Study: 26940547

Group type: EXPERIMENTAL
Intervention: Community-wide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School-based treatment
Number of subjects: 0
Study: 24831368

Group type: EXPERIMENTAL
Intervention: Single burr hole
Number of subjects: 254

Group type: COMPARATOR
Intervention: Double burr hole
Number of subjects: 254